Infliximab in the treatment of severe, steroid-refractory ulcerative colitis

A pilot study

Bruce E. Sands, Wolfgang Miehsler, William J. Tremaine, Paul J. Rutgeerts, Stephen B. Hanauer, Lloyd Mayer, Stephan R. Targan, Daniel K. Podolsky

Research output: Contribution to journalArticle

355 Citations (Scopus)

Abstract

We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind, placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory ulcerative colitis. The study was terminated prematurely because of slow enrollment. Patients having active disease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids were eligible to receive a single intravenous infusion of infliximab at 5, 10, or 20 mg/kg body weight. The primary endpoint used in this study was treatment failure at 2 weeks after infusion. Treatment failure was defined as 1) unachieved clinical response as defined by a modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death. Safety evaluations included physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences. Four of 8 patients (50%) who received infliximab were considered treatment successes at 2 weeks, compared with none of 3 patients who received placebo. Improvement in erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6 correlated with the clinical response observed in patients receiving infliximab. Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalInflammatory Bowel Diseases
Volume7
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Ulcerative Colitis
Steroids
Therapeutics
Treatment Failure
Adrenal Cortex Hormones
Placebos
Clinical Chemistry
Infliximab
Colectomy
Blood Sedimentation
Controlled Clinical Trials
Hematology
Immunosuppressive Agents
Intravenous Infusions
C-Reactive Protein
Physical Examination
Interleukin-6
Body Weight
Safety
Serum

Keywords

  • Infliximab
  • Monoclonal antibody
  • Steroid-refractory
  • Tumor necrosis factor alpha
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis : A pilot study. / Sands, Bruce E.; Miehsler, Wolfgang; Tremaine, William J.; Rutgeerts, Paul J.; Hanauer, Stephen B.; Mayer, Lloyd; Targan, Stephan R.; Podolsky, Daniel K.

In: Inflammatory Bowel Diseases, Vol. 7, No. 2, 2001, p. 83-88.

Research output: Contribution to journalArticle

Sands, BE, Miehsler, W, Tremaine, WJ, Rutgeerts, PJ, Hanauer, SB, Mayer, L, Targan, SR & Podolsky, DK 2001, 'Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study', Inflammatory Bowel Diseases, vol. 7, no. 2, pp. 83-88. https://doi.org/10.1097/00054725-200105000-00001
Sands, Bruce E. ; Miehsler, Wolfgang ; Tremaine, William J. ; Rutgeerts, Paul J. ; Hanauer, Stephen B. ; Mayer, Lloyd ; Targan, Stephan R. ; Podolsky, Daniel K. / Infliximab in the treatment of severe, steroid-refractory ulcerative colitis : A pilot study. In: Inflammatory Bowel Diseases. 2001 ; Vol. 7, No. 2. pp. 83-88.
@article{da839254b1a540ee8a1df2064c2fbb49,
title = "Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study",
abstract = "We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind, placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory ulcerative colitis. The study was terminated prematurely because of slow enrollment. Patients having active disease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids were eligible to receive a single intravenous infusion of infliximab at 5, 10, or 20 mg/kg body weight. The primary endpoint used in this study was treatment failure at 2 weeks after infusion. Treatment failure was defined as 1) unachieved clinical response as defined by a modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death. Safety evaluations included physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences. Four of 8 patients (50{\%}) who received infliximab were considered treatment successes at 2 weeks, compared with none of 3 patients who received placebo. Improvement in erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6 correlated with the clinical response observed in patients receiving infliximab. Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis.",
keywords = "Infliximab, Monoclonal antibody, Steroid-refractory, Tumor necrosis factor alpha, Ulcerative colitis",
author = "Sands, {Bruce E.} and Wolfgang Miehsler and Tremaine, {William J.} and Rutgeerts, {Paul J.} and Hanauer, {Stephen B.} and Lloyd Mayer and Targan, {Stephan R.} and Podolsky, {Daniel K.}",
year = "2001",
doi = "10.1097/00054725-200105000-00001",
language = "English (US)",
volume = "7",
pages = "83--88",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Infliximab in the treatment of severe, steroid-refractory ulcerative colitis

T2 - A pilot study

AU - Sands, Bruce E.

AU - Miehsler, Wolfgang

AU - Tremaine, William J.

AU - Rutgeerts, Paul J.

AU - Hanauer, Stephen B.

AU - Mayer, Lloyd

AU - Targan, Stephan R.

AU - Podolsky, Daniel K.

PY - 2001

Y1 - 2001

N2 - We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind, placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory ulcerative colitis. The study was terminated prematurely because of slow enrollment. Patients having active disease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids were eligible to receive a single intravenous infusion of infliximab at 5, 10, or 20 mg/kg body weight. The primary endpoint used in this study was treatment failure at 2 weeks after infusion. Treatment failure was defined as 1) unachieved clinical response as defined by a modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death. Safety evaluations included physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences. Four of 8 patients (50%) who received infliximab were considered treatment successes at 2 weeks, compared with none of 3 patients who received placebo. Improvement in erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6 correlated with the clinical response observed in patients receiving infliximab. Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis.

AB - We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind, placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory ulcerative colitis. The study was terminated prematurely because of slow enrollment. Patients having active disease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids were eligible to receive a single intravenous infusion of infliximab at 5, 10, or 20 mg/kg body weight. The primary endpoint used in this study was treatment failure at 2 weeks after infusion. Treatment failure was defined as 1) unachieved clinical response as defined by a modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death. Safety evaluations included physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences. Four of 8 patients (50%) who received infliximab were considered treatment successes at 2 weeks, compared with none of 3 patients who received placebo. Improvement in erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6 correlated with the clinical response observed in patients receiving infliximab. Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis.

KW - Infliximab

KW - Monoclonal antibody

KW - Steroid-refractory

KW - Tumor necrosis factor alpha

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0034777502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034777502&partnerID=8YFLogxK

U2 - 10.1097/00054725-200105000-00001

DO - 10.1097/00054725-200105000-00001

M3 - Article

VL - 7

SP - 83

EP - 88

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -